| Nome |
# |
|
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, file e398c37f-8b18-179a-e053-3705fe0a4cff
|
1622
|
|
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report, file e398c37f-f7af-179a-e053-3705fe0a4cff
|
279
|
|
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect, file e398c37f-986f-179a-e053-3705fe0a4cff
|
273
|
|
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy, file e398c37b-dc11-179a-e053-3705fe0a4cff
|
135
|
|
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification, file e398c37d-8ffc-179a-e053-3705fe0a4cff
|
113
|
|
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles, file e398c381-42cf-179a-e053-3705fe0a4cff
|
113
|
|
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC, file e398c37f-25b8-179a-e053-3705fe0a4cff
|
106
|
|
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients, file e398c37f-2d70-179a-e053-3705fe0a4cff
|
103
|
|
Regorafenib also can cause osteonecrosis of the jaw, file e398c37f-9789-179a-e053-3705fe0a4cff
|
80
|
|
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation, file e398c380-60f9-179a-e053-3705fe0a4cff
|
74
|
|
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy, file e398c381-6307-179a-e053-3705fe0a4cff
|
72
|
|
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience, file 795c501b-bca5-4723-9583-b1579276acab
|
68
|
|
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study, file e398c380-273f-179a-e053-3705fe0a4cff
|
57
|
|
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues, file e398c381-5759-179a-e053-3705fe0a4cff
|
42
|
|
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives, file e398c381-c65a-179a-e053-3705fe0a4cff
|
38
|
|
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study, file 58c16146-9012-4ed6-870f-85ad58b4f0ae
|
29
|
|
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions, file 59250bc1-0a9d-40ef-bc34-451777c0627c
|
27
|
|
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report, file e398c381-f470-179a-e053-3705fe0a4cff
|
25
|
|
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis, file b927e36e-7fc7-4d00-952e-2023fb3e96ef
|
20
|
|
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes, file f64c687b-6c22-4d37-90e5-4fa181859088
|
19
|
|
Current status and future perspectives in HER2 positive advanced gastric cancer, file cf65e2a8-80f2-4376-b476-6e0193f6089a
|
15
|
|
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations", file 8c6564f8-d548-4761-9485-c272fc934471
|
13
|
|
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study, file f212f5ad-0bff-4397-a1d6-386caf9398f2
|
13
|
|
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50, file 16dc0469-bf34-499a-997f-a3b9862cd9a6
|
12
|
|
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET, file 9adc6d62-4248-4ff7-8648-fb12e72e91a4
|
12
|
|
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial, file 876bc7b7-c9c8-45af-a5be-86ffaf69dc04
|
11
|
|
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression, file b8397d36-45cb-45bb-9e35-2b786148e8bc
|
11
|
|
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas, file f6c6f987-b244-4030-bd97-7e7ca41221e0
|
10
|
|
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research, file 65793f65-8550-4ba9-8528-75c7789a3fd0
|
8
|
|
The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers, file b1af915a-33ab-4336-be50-ceaa2470df47
|
8
|
|
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough, file d997b904-8854-42d9-8d21-0040c06d892d
|
8
|
|
Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma, file 1fff05f5-034d-442f-b68c-93111813d6be
|
7
|
|
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature, file 65eb34f3-abd3-4838-8cee-770ca8885aea
|
7
|
|
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy, file 9b9ef512-b36d-44f9-ae2c-83656d8b1804
|
7
|
|
Liquid biopsy in colorectal cancer: No longer young, but not yet old, file 3367c1d0-e6d1-4595-9141-cc1314a3f48e
|
5
|
|
Somatostatin analogs in pregnant patients with neuroendocrine tumor, file 488cbb9c-29ea-417a-b090-f1465cd91e18
|
5
|
|
Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity, file 63641d27-ced3-4b1d-9e1e-f2636e4720a7
|
5
|
|
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study, file a8a0c453-2910-4d75-b02c-d8001ddb372f
|
5
|
|
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy, file 255c5b8d-1718-48eb-92cb-c9e72064d9b7
|
4
|
|
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy, file 39347298-54c6-4987-ad37-b2fba144a619
|
4
|
|
Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors?, file 5cc6b2fc-5dcb-400f-81da-a8d6a84271dd
|
4
|
|
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study, file b548539b-0955-4439-bb6b-9f0aa189e572
|
4
|
|
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors, file b9a6189c-e6e8-4bea-ad70-40ccf94873d5
|
4
|
|
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial, file 6c233232-c7aa-43db-9c62-dbdcfdd4c1ec
|
3
|
|
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors, file 8ab3701e-04d1-4f37-8dac-6c8b1a28dbe6
|
3
|
|
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience, file a61dad1a-fed8-47b6-9b54-f06eaca061cf
|
3
|
|
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program, file af263b64-e950-48fe-a67a-1c9e0890cb81
|
3
|
|
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size, file dd3cf631-4213-45dc-b330-54cb8f0270c5
|
3
|
|
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital, file e5cfdabe-3b62-4f56-ba1f-f3bd6183aa57
|
3
|
|
SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY PERCUTANEOUS ETHANOL INJECTION: A 10-YEAR EXPERIENCE., file 03b31bf0-5761-439a-896b-847d1bda56a5
|
2
|
|
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study, file 1421b14a-2df0-4c85-8aef-24ab0ee60231
|
2
|
|
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study, file 2b1737ef-83b1-4b7a-aba8-4f0eea1526dd
|
2
|
|
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study, file 5b909700-0c27-405c-917b-1fe6664ae342
|
2
|
|
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer, file 7d4e2577-3346-4dea-ac46-84412fa88dad
|
2
|
|
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram, file 81b3a424-968d-4e48-b90e-9f612e7f2f93
|
2
|
|
Response, file a138f7a7-771b-4f4e-abfc-81d4aad4001d
|
2
|
|
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509), file a5b78649-bcee-41c7-a87e-79cb3a6df95b
|
2
|
|
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018), file ab5ac292-7763-41a5-b5e0-33d10f7efa4a
|
2
|
|
Systemic Sclerosis Association with Malignancy, file b3f911bf-019f-4b17-a3da-0e8ba173043d
|
2
|
|
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives, file b5d79bbc-b7aa-4962-8264-15b1faaa9582
|
2
|
|
Real-world study of everolimus in advanced progressive neuroendocrine tumors, file d014b3cf-edf9-480a-8e71-5fcb232a5641
|
2
|
|
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors, file d0987aa9-4af6-473b-81dd-d87f6597f01c
|
2
|
|
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues, file e398c381-5996-179a-e053-3705fe0a4cff
|
2
|
|
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors, file f0f95dfa-8abd-4ed8-bbae-5ec7ba53a2c2
|
2
|
|
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment, file 0e498886-161d-4f1f-9ca8-037b979d22e8
|
1
|
|
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world, file 111b6fdc-9a5e-432d-bd48-883d5fbd87da
|
1
|
|
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification, file 19292ede-1a42-4a45-99ca-34546035b908
|
1
|
|
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma, file 28ee018a-8ac3-43bd-82d9-e061ba73578d
|
1
|
|
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors, file 4aff37c8-7f3c-4e84-9d17-454b22c448d5
|
1
|
|
Metastatic gastric cancer in the last two decades: Goals achieved and future promises, file 4cc44a34-a48c-4f3b-84aa-36a6ccbf4f11
|
1
|
|
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study, file 4e7292fd-ba69-4fbb-a6a0-7e4860918350
|
1
|
|
Primary cardiac angiosarcoma: a fatal disease, file 68322087-bf23-4bec-bdf3-d50176c8614c
|
1
|
|
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature, file 72ee5883-5417-4322-a0d7-a052a4a86e3c
|
1
|
|
Results of the observational prospective RealFLOT study, file 766c0e2b-ef12-4d4c-9811-5c44a4a5534e
|
1
|
|
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population, file 7ad613dd-4f8c-4c05-83c0-0b61cb40587f
|
1
|
|
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective, file 7ef91b72-6e41-4cd4-96a2-f15f02e05cc6
|
1
|
|
Practical considerations in the use of regorafenib in metastatic colorectal cancer, file 8594540b-333d-44a8-a81e-d51956691286
|
1
|
|
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer, file 8bbbaf25-d6dc-4398-b7e6-eb28870c31de
|
1
|
|
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations, file 921ea763-de8b-4349-92c3-ac53c5ca400e
|
1
|
|
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards, file 930b843d-fffe-4f76-997e-79c78482782a
|
1
|
|
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM), file a25a0b68-e4e6-4aef-9afa-9c3a4753b5ce
|
1
|
|
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours, file a2831f94-1fa9-4f7a-9916-caa88c99e3b9
|
1
|
|
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma, file aa3e259e-260d-4655-abe9-a2f7e9aa661e
|
1
|
|
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram, file c490ddc0-7e81-45da-8d91-58b316766ee1
|
1
|
|
Skin metastasis from typical carcinoid tumor of the lung., file c8158f02-3875-4e6e-b4dc-408e262de02d
|
1
|
|
ROS1 rearrangements are uncommon in biliary tract cancers, file cf424955-6c10-4861-b8d0-2db10f22157d
|
1
|
|
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience, file d5c46122-997b-4e10-bab6-0a9659cdb2f0
|
1
|
|
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario, file dc33da98-49dd-4fdc-a136-8ef1a187409e
|
1
|
|
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study), file e61277c8-c13c-48bc-9ef6-dd4aa9dead10
|
1
|
|
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer, file eaa8ac77-b63d-4973-9b71-95585690e0a4
|
1
|
|
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer, file f7ea65bd-03f9-41b9-a069-4f44aae4ab38
|
1
|
|
Molecular classifications of gastric cancers: Novel insights and possible future applications, file f95dca64-fe82-424b-85fc-4420147ec330
|
1
|
| Totale |
3553 |